NVCR outlook set for double-digit growth on launches, payer gains
Optune Pax’s stage III pancreatic cancer launch exceeded expectations with a 70% prescription-to-active patient conversion and early payer coverage. NVCR also cites Europe and Japan expansion, new clinical trials, and disciplined financial management.